builderall

Conference Description

This program focuses on the dissemination of emerging clinical evidence and comprehensive oral and intravenous pharmacotherapy management strategies across a variety of specialties. The exponential growth of specialty therapies, coupled with increasing utilization of multiple lines of treatment, calls for close oversight of an expanding and increasingly complex therapeutic landscape. Concurrent advances in diagnostics and the rapid evolution of precision medicine continue to shape individualized treatment selection and sequencing.

Given the magnitude and pace of emerging scientific evidence, it is essential that pharmacists are equipped with cutting-edge, evidence-based education to support optimal therapy options. This summit also emphasizes the identification of best practices that address the unique challenges and opportunities related to patient access while driving operational efficiency and value for provider organizations.

By design, this program convenes subject matter experts and local leaders to highlight both clinical and practical considerations related to emerging specialty pharmaceuticals across oncology and malignant hematology, as well as breakthrough therapeutic advancements in other disease states, including neurology, cardiology, and endocrinology. The summit content will underscore the critical role of pharmacists in optimizing patient adherence, as well as best practices related to the utilization of biosimilars, 505(b)(2) products, intravenous versus subcutaneous formulations, and bispecific therapies in both hematologic malignancies and solid tumors. Additional discussions will address key practice considerations, including navigating payer authorizations, managing drug utilization, and evaluating practice expansion opportunities driven by the continued growth of specialty infusion. Throughout, these sessions will highlight strategies across the ecosystem of stakeholders that collectively establish access to specialty pharmaceuticals.

Target Audience & Expected Attendance

This educational activity has been designed to meet the educational needs of all pharmacy professionals, including pharmacists and pharmacy technicians. Expected attendance: 120 professionals.

Learner Objectives

After participating in SPS Twin Cities, learners will be better able to:

 Identify emerging specialty pharmacotherapy options

 Discuss therapy management and monitoring considerations

 Recognize strategies to drive optimal therapy outcomes

 Distinguish strategies to drive multi-stakeholder efficiencies and value